Ergebnisse der PROSPECT-Studie: Eine randomisierte Phase-III-Studie von PROSTVAC-V/F (PRO) bei Männern mit asymptomatischem oder minimal symptomatisch metastasierendem kastrationsresistentem Prostatakarzinom

ASCO Annual Meeting 2018 – Abstract: No. 5006, Gulley, JL et al.: PROSTVAC-V/F (PRO)-Studie

Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer.

 

Conclusion:

“PROSPECT failed to confirm an OS benefit observed in a prior RandPh2. Of interest, OS observed in all arms was approximately one year longer than anticipated based upon historical controls, likely related to improved standard of care since study enrollment began in 2011.”

 

Clinical trial information: NCT01322490

 

Quelle:
Gulley, JL et al. ASCO 2018, Oral Abstract Session, Genitourinary (Prostate) Cancer

J Clin Oncol 36, 2018 (suppl; abstr 5006)

https://meetinglibrary.asco.org/record/160547/abstract